Corcept Therapeutics (CORT) Short-term Investments (2017 - 2026)

Corcept Therapeutics has reported Short-term Investments for 10 years, with the latest figure at $197.2 million in Q2 2026.

• Quarterly Short-term Investments fell 17.67% year-over-year to $197.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $197.2 million (down 17.67% YoY) and the FY2025 annual result came in at $251.7 million, down 1.57% from the prior year.
• Short-term Investments eased to $197.2 million in Q2 2026 per CORT's latest filing, from $229.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $365.3 million in Q4 2022 and troughed at $165.1 million in Q1 2023.
• A 5-year average of $261.9 million and a median of $247.5 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments surged 150.38% in 2022, then tumbled 42.98% in 2023.
• Over 5 years, Short-term Investments stood at $365.3 million in 2022, then tumbled by 36.31% to $232.7 million in 2023, then rose by 9.88% to $255.7 million in 2024, then retreated by 1.57% to $251.7 million in 2025, then declined by 21.66% to $197.2 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $197.2 million, $229.4 million, and $251.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.